At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 84 enrolled
Drug / intervention
liraglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
LIRAGLUTIDE IN OVERWEIGHT PATIENTS WITH TYPE 1 DIABETES
In Brief
A Phase 3 clinical trial evaluating liraglutide and placebo for Type 1 Diabetes. Completed, enrolled 84 participants across 2 sites.
Detailed Summary
The purpose of this study is to examine the effects of liraglutide (a drug used to treat type 2 diabetes) on glucose (sugar) control over the 26 week study period when used in addition to insulin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesUnited States
CollaboratorsJuvenile Diabetes Research Foundation
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2012
First PostedDec 2012
Primary CompletionDec 2017
Study CompletionFeb 2018
TodayJul 2026
First PostedDec 20, 2012
Enrollment StartDec 1, 2012
Primary CompletionDec 1, 2017
Study CompletionFeb 1, 2018
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 13.5 years ago
Interventions
liraglutidedrug
placebodrug